Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e18565
Abstract: e18565Introduction: Hydroxyurea (HU) is deemed first-line cytoreductive therapy for patients with essential thrombocythemia (ET) at high-risk for vascular complications with 20-25% of patients deve...
read more here.
Keywords:
intolerant resistant;
essential thrombocytopenia;
thrombocytopenia patients;
hydroxyurea ... See more keywords